Cargando…
Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders
Aberrant expression ratio of Cl(−) transporters, NKCC1 and KCC2, is implicated in several brain conditions. NKCC1 inhibition by the FDA-approved diuretic drug, bumetanide, rescues core symptoms in rodent models and/or clinical trials with patients. However, bumetanide has a strong diuretic effect du...
Autores principales: | Savardi, Annalisa, Borgogno, Marco, Narducci, Roberto, La Sala, Giuseppina, Ortega, Jose Antonio, Summa, Maria, Armirotti, Andrea, Bertorelli, Rosalia, Contestabile, Andrea, De Vivo, Marco, Cancedda, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427514/ https://www.ncbi.nlm.nih.gov/pubmed/32818158 http://dx.doi.org/10.1016/j.chempr.2020.06.017 |
Ejemplares similares
-
Design, Synthesis, In Vitro and In Vivo Characterization of Selective NKCC1 Inhibitors for
the Treatment of Core Symptoms in Down Syndrome
por: Borgogno, Marco, et al.
Publicado: (2021) -
Novel, Potent,
and Druglike Tetrahydroquinazoline
Inhibitor That Is Highly Selective for Human Topoisomerase II α
over β
por: Ortega, Jose Antonio, et al.
Publicado: (2020) -
Structural basis for inhibition of the Cation-chloride cotransporter NKCC1 by the diuretic drug bumetanide
por: Zhao, Yongxiang, et al.
Publicado: (2022) -
Design, Synthesis, In Vitro and In Vivo Characterization of
CDC42 GTPase Interaction Inhibitors
for the Treatment of Cancer
por: Brindani, Nicoletta, et al.
Publicado: (2023) -
Design, Synthesis,
Dynamic Docking, Biochemical Characterization,
and in Vivo Pharmacokinetics Studies of Novel Topoisomerase
II Poisons with Promising Antiproliferative Activity
por: Arencibia, Jose M., et al.
Publicado: (2020)